Exclusive: DeepMind’s Demis Hassabis unveils his vision for Isomorphic and AI’s future in biotech

While Demis Has­s­abis is best known for steer­ing Al­pha­bet’s re­search ef­forts in ar­ti­fi­cial in­tel­li­gence, the 47-year-old is si­mul­ta­ne­ous­ly lead­ing a se­cre­tive biotech start­up look­ing to bring about an AI rev­o­lu­tion in drug dis­cov­ery.

Has­s­abis is the CEO of Google Deep­Mind as well as Iso­mor­phic Labs, an Al­pha­bet-backed com­pa­ny found­ed in 2021 to take Deep­Mind’s AI re­search in bi­ol­o­gy fur­ther in­to the drug in­dus­try. Deep­Mind has won a myr­i­ad of awards for Al­phaFold2, its AI sys­tem that pre­dicts pro­tein struc­tures and was pub­lished in 2021. Head­quar­tered in Lon­don, Iso­mor­phic has shared few de­tails about what it’s work­ing on in its rough­ly two years of ex­is­tence.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.